AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for MAP/microtubule affinity-regulating kinase 4

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q96L34

UPID:

MARK4_HUMAN

Alternative names:

MAP/microtubule affinity-regulating kinase-like 1

Alternative UPACC:

Q96L34; Q8NG37; Q96JG7; Q96SQ2; Q9BYD8

Background:

MAP/microtubule affinity-regulating kinase 4, also known as MAP/microtubule affinity-regulating kinase-like 1, is a serine/threonine-protein kinase. It plays a crucial role in phosphorylating microtubule-associated proteins such as MAPT/TAU, MAP2, and MAP4, leading to the reorganization of microtubules into bundles. This kinase is essential for axoneme extension during cilium assembly and influences cell cycle progression, particularly at the G1/S checkpoint. It also impacts neuronal cell survival, energy homeostasis, adipogenesis, and apoptosis through various signaling pathways.

Therapeutic significance:

Understanding the role of MAP/microtubule affinity-regulating kinase 4 could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.